Chemistry:Ravidasvir
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | PPI-668 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C42H50N8O6 |
| Molar mass | 762.912 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]
It is on the World Health Organization's List of Essential Medicines.[2]
Preliminary clinical trial results were announced in Nov 2015.[3] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[4] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.[5][6]
References
- ↑ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
- ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.
- ↑ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. November 24, 2015. https://www.hepmag.com/article/PYRAMID-Sovaldi-ravidasvir-28085-1528583872.
- ↑ "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian. 13 April 2018. https://www.theguardian.com/science/2018/apr/12/non-profits-300-hepatitis-c-cure-as-effective-as-84000-alternative.
- ↑ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia". https://www.npra.gov.my/easyarticles/images/users/1047/Produk-yang-diluluskan-dalam-DCA-358-4-Jun-2021.pdf.
- ↑ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi" (in en-GB). 2021-06-14. https://dndi.org/press-releases/2021/first-hepatitis-c-treatment-developed-through-south-south-cooperation-registered-in-malaysia/.
 |
